| Title: |
Gemtuzumab ozogamicin in first-line treatment of CBF-AML : insights from a retrospective multi-center analysis : acute myeloid leukemia |
| Authors: |
Ronnacker, Julian; Muller, Philippe J.; Mikesch, Jan-Henrik; Zukunft, Sven; Weinbergerová, Barbora; Šrámek, Jiří; Valka, Jan; Novak, Jan; Zak, Pavel; Szotkowski, Tomas; Koristek, Zdenek; Krekeler, Carolin; Unglaub, Julia Marie; Sauer, Tim; Ruhnke, Leo; Kraus, Sabrina; Schaffrath, Judith; Müller, Lutz P.; Kaes, Sabrina; Niemann, Dirk; Fransecky, Lars; Hess, Patrick P.; Crysandt, Martina; Jost, Edgar; Millo, Joana; Gaertner, Johannes; Repp, Roland; Jentzsch, Madlen; Hoppe, Lea; Klein, Stefan; Modemann, Franziska; Michalowski, Nina; Fischbach, Klaudia; Blau, Wolfgang; Ruhs, Marion; Ritter, Markus; Lohmeyer, Julian; Steffen, Björn; Hauser, Sarah; Kaufmann, Martin; Krause, Stefan W.; Knabe, Ricarda; Spiekermann, Karsten; Serve, Hubert; Platzbecker, Uwe; Baldus, Claudia D.; Müller-Tidow, Carsten; Lenz, Georg; Reinhardt, Hans Christian; Mayer, Jirí; Bornhäuser, Martin; Röllig, Christoph; Schliemann, Christoph; Hanoun, Maher |
| Publication Year: |
2025 |
| Collection: |
Share it - Open Access und Forschungsdaten-Repositorium der Hochschulbibliotheken in Sachsen-Anhalt |
| Subject Terms: |
ddc:610 |
| Description: |
The addition of gemtuzumab ozogamicin (GO) to intensive chemotherapy (IC) has become a mainstay in treating patients with core binding factor acute myeloid leukemia (CBF-AML). However, evidence for the efficacy of GO in this particular subgroup is primarily based on meta-analytic data from different trials conducted more than a decade ago. In this registry-based study, we evaluated the impact of adding GO to IC in 265 CBF-AML patients from the SAL, AMLCG, and CELL cooperative study groups. Patients receiving GO had a 2-year overall survival of 90% compared with 80% in those without GO (hazard ratio [HR] 0.45, 95% confidence interval [CI] 0.21-0.95, P = 0.036) and a 2-year event-free survival of 51% versus 36% (HR 0.69, 95% CI 0.48-0.99, P = 0.046). While complete remission rates in GO vs. non-GO patients were comparable (89% vs. 90%, P = 0.81), more GO patients achieved measurable residual disease-negative remission (77% vs. 49%, P < 0.001), resulting in numerically reduced cumulative incidence of relapse (HR 0.67, 95% CI 0.43-1.02, P = 0.06). Despite delayed platelet recovery, high-grade toxicities were not increased in GO-treated patients. These findings support the integration of GO into treatment protocols for IC-eligible patients with CBF-AML. ; Gesehen am 16.09.2025 |
| Document Type: |
article in journal/newspaper |
| File Description: |
application/pdf |
| Language: |
English |
| ISBN: |
978-1-936161-25-6; 1-936161-25-7 |
| Relation: |
http://dx.doi.org/10.25673/120891 |
| DOI: |
10.25673/120891 |
| Availability: |
https://opendata.uni-halle.de//handle/1981185920/122847; https://doi.org/10.25673/120891 |
| Rights: |
https://creativecommons.org/licenses/by/4.0/ |
| Accession Number: |
edsbas.338AC64D |
| Database: |
BASE |